Understanding cardiac failure in patients with chronic kidney disease Aug 1, 2018 - Jan 31, 2019
As previously shown Chronic Kidney Disease (CKD) patients have additional cardiovascular risk associated with increased mortality. Uraemic Cardiomyopathy (UCM) a frequent finding in CKD contributes to the poor clinical outcomes. Prof Bhandair and col...
Read More about Understanding cardiac failure in patients with chronic kidney disease.
Projects (482)
TRANSFORM: Effects of physical activity during the cancer journey Jun 1, 2018 - May 31, 2024
Regular physical activity has been shown to help improve the body and mind during and after cancer treatment. Regular activity has also been linked to lower risk of cancer recurring and to longer survival. Despite this, most people with a cancer diag...
Read More about TRANSFORM: Effects of physical activity during the cancer journey.
TRANSFORM: Clinical research fellows Sep 1, 2018 - Dec 31, 2026
This award from Yorkshire Cancer Research was a capacity building grant to support six clinical doctoral fellowships. These were awarded to:
Arwa Abdel-Aal: Social Inequalities in Uptake of Five Different Ways of Delivering Lung Cancer Screening...
Read More about TRANSFORM: Clinical research fellows.
STATIC: A Randomised Phase III Trial Comparing Continuous with Intermittent Treatment Strategies in Chronic Lymphocytic Leukaemia (CLL) Jan 1, 2021 - Mar 31, 2031
Chronic lymphocytic leukaemia (CLL) is a cancer that affects the blood and bone marrow. It tends to progress slowly, and is incurable. CLL is the most common leukaemia in adults. The first treatment for CLL is chemotherapy. This is usually given for...
Read More about STATIC: A Randomised Phase III Trial Comparing Continuous with Intermittent Treatment Strategies in Chronic Lymphocytic Leukaemia (CLL).
Evaluating EV as a therapeutic target in Graves’ disease Feb 1, 2019 - Dec 31, 2020
Evaluating EV as a therapeutic target in Graves’ disease
Graves’ disease is an autoimmune disease characterised by elevated circulating autoantibodies to the thyrotropin receptor (TRAB), resulting in hyperthyroidism. Inflammation, characteristic o...
Read More about Evaluating EV as a therapeutic target in Graves’ disease.
Development and pilot of the “Living with Polycystic Ovary Syndrome (PCOS)” structured education programme Apr 1, 2019 - Sep 30, 2021
Polycystic ovary syndrome (PCOS) is the most common endocrine condition in reproductive age group females and it is associated with various clinical features including irregular periods, male-pattern hair loss from the head and excess hair in other b...
Read More about Development and pilot of the “Living with Polycystic Ovary Syndrome (PCOS)” structured education programme.
A single arm, open-label exploratory clinical trial of azithromycin in pulmonary sarcoidosis Mar 1, 2019 - Sep 30, 2020
Patients with sarcoidosis need treatment options that improve their disease without causing unacceptable side effects. Currently, steroids tablets are offered for severe sarcoidosis, but side effects can be dangerous and personally distressing, and s...
Read More about A single arm, open-label exploratory clinical trial of azithromycin in pulmonary sarcoidosis.
Partners in Practice Sep 23, 2019 - Mar 31, 2022
The East Riding of Yorkshire Council (ERYC) Partners in Practice (PiP) programme is part of a Department for Education funded initiative aimed at improving outcomes for children, young people and their families known to social care services by ensuri...
Read More about Partners in Practice.
AZD9977: A Phase I, Open Label, Randomized, Parallel group, Multicentre study to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium [sK+] during 28 days in Patients with HFmrEF or HFpEF and eGFR in the range of ≥40 and ≤70 mL/min/1.73m2 Feb 1, 2019 - Jan 31, 2020
A Phase I, Open Label, Randomized, Parallel group, Multicentre study to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium [sK+] during 28 days in Patients with HFmrEF or HFpEF
and eGFR in the range of ≥40 and ≤70 mL/min/1.73m2.
Is zinc a critical modulator of cyclic nucleotide signalling? Oct 1, 2019 - Dec 31, 2022
inc (Zn2+) deficiency is present in multiple conditions from obesity to cancer. However importantly Zn2+ deficiency can lead to a bleeding phenotype.In this proposal we investigate how Zn2+ is important for the control of platelet cyclic nucleotide...
Read More about Is zinc a critical modulator of cyclic nucleotide signalling?.
Matrix Metalloproteinase Activated Multimodal 'Theranostic' Drug Delivery Imaging Agents For Thrombosis Mar 1, 2020 - Aug 31, 2024
PROMS: CPR Cancer outcomes: The use of comprehensive patient records (CPR) to define the impact of cancer, co-morbidities and late effects on individuals and the health service Sep 30, 2015 - Jun 30, 2019
The ageing population and increasing success of cancer services has resulted in more people living for long periods with and beyond a diagnosis of cancer. Whilst we know that many people living beyond a cancer diagnosis report unmet needs, there is i...
Read More about PROMS: CPR Cancer outcomes: The use of comprehensive patient records (CPR) to define the impact of cancer, co-morbidities and late effects on individuals and the health service.
Development of an immune-responsive 3D skin model May 1, 2019 - Jul 31, 2019
The immune system is an essential regulator of normal physiologic and wound repair processes within the skin, and it contributes to the progression of many different skin diseases. The nature of the interactions between circulating immune cells and r...
Read More about Development of an immune-responsive 3D skin model.
Novel dual CXCR4/CXCR7 receptor drugs: targeting secondary disease progression and resistance to immunotherapy in breast cancer Aug 1, 2019 - Jul 31, 2023
CXCR4/CXCR7-CXCL12 chemokine axis plays a pivotal role in breast cancer (BC) growth, survival, therapy evasion and metastasis. Clinically overexpression of CXCR4/CXCR7-CXCL12 correlates with aggressive BC disease and poor outcome. Evidence suggests c...
Read More about Novel dual CXCR4/CXCR7 receptor drugs: targeting secondary disease progression and resistance to immunotherapy in breast cancer.
I3: Building Critical Mass, Increasing Scale and Impact for Palliative Care through International Collaboration Aug 1, 2019 - Mar 31, 2025
The world population is ageing and, with the growth of multi-morbidities, UK deaths are expected to increase by 40% by 2040. New models of care and treatments are urgently needed to improve quality of life for the significantly increased numbers of p...
Read More about I3: Building Critical Mass, Increasing Scale and Impact for Palliative Care through International Collaboration.
Utilising tissue-on-a-chip technology as an ex vivo model of breast cancer metastatic colonisation Jul 1, 2019 - Mar 31, 2021
Breast cancer kills over 11,000 women each year in the UK. Virtually all of these women die because their breast cancer cells travel to other organs within the body such as the liver, lungs, bones and brain, where they grow into new tumours and stop...
Read More about Utilising tissue-on-a-chip technology as an ex vivo model of breast cancer metastatic colonisation.
The incidence and impact of incivility in pre-hospital care Feb 1, 2019 - Jan 31, 2020
Study aim: To evaluate registered paramedics perception of incivility in clinical practice
Study objectives:
1. To conduct semi-structured interviews with registered paramedics to identify the incidence of incivility
2. To explore the paramedic...
Read More about The incidence and impact of incivility in pre-hospital care.